Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ • Healthcare

$9.5

+$0.44 (+5.0%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$8.89 - $9.55

Avg. Volume (3M)1.1M

Market Cap$768.5M

52 Week Range

$8.21$18.31

Next EarningsIn 54 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$74.2M100%

Gross Profitminus cost of goods$59.1M80%

In plain terms: out of every $100 in revenue, Phathom Pharmaceuticals, Inc. currently loses $24.

Fundamentals & Financials

Revenue (TTM)

$239.6M

Net Income (TTM)

-$99M

EPS (TTM)

-$1.28

ROA (TTM)

-30.29%

Current Ratio

1.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-3.9%Q3 2025-$0.79

-2.5%Q4 2025-$0.41

+9.2%Q1 2026-$0.29

-37.0%Q2 2026-$0.37

-19.6%Q3 2026-$0.21

Oct 29

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on vonoprazan, a potassium-competitive acid blocker that suppresses gastric acid production. The company generated $175.1 million in FY2025 revenue from this gastrointestinal franchise and centers its business on developing and commercializing the medicine in Western markets.

Name

Phathom Pharmaceuticals, Inc.

CEO

Steven L. Basta

Website

www.phathompharma.com

Industry

Healthcare

Year Founded

2018

Employees

371

Today's Snapshot

AI-generated

PHAT closed 5% higher at 9.50, outperforming a weaker sector. Shares changed hands at about a quarter more than its usual level. Phathom Pharmaceuticals narrowed its quarterly loss as revenue rose.

Trading Volume

Above 10d avg 940.2K

1.2M

vs S&P 500 Today

Strong Outperformance

+5.39%

Updated: September 4, 2026 at 20:10 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

PHAT registers a neutral technical stance as short-term averages sit at or just below the market while longer-term averages remain notably higher, creating a mixed moving-average picture. Momentum and oscillators are near neutral and MACD is slightly negative, while ADX points to a weak trend and ATR flags above-average percentage volatility. On-balance volume is positive, offering some support, and the classic pivot aligns near the shorter-term average. Technical takeaway: neutral — near-term buying pressure balances longer-term resistance, leaving no clear directional edge.

All signals